Judith Falloon

10.1k total citations · 1 hit paper
91 papers, 6.7k citations indexed

About

Judith Falloon is a scholar working on Infectious Diseases, Epidemiology and Virology. According to data from OpenAlex, Judith Falloon has authored 91 papers receiving a total of 6.7k indexed citations (citations by other indexed papers that have themselves been cited), including 50 papers in Infectious Diseases, 37 papers in Epidemiology and 35 papers in Virology. Recurrent topics in Judith Falloon's work include HIV/AIDS drug development and treatment (38 papers), HIV Research and Treatment (35 papers) and HIV/AIDS Research and Interventions (22 papers). Judith Falloon is often cited by papers focused on HIV/AIDS drug development and treatment (38 papers), HIV Research and Treatment (35 papers) and HIV/AIDS Research and Interventions (22 papers). Judith Falloon collaborates with scholars based in United States, Spain and United Kingdom. Judith Falloon's co-authors include Henry Masur, H. Clifford Lane, Richard T. Davey, Joseph A. Kovacs, Julia A. Metcalf, Michael A. Polis, Robert Walker, Michael Baseler, Stephen C. Piscitelli and Robin Dewar and has published in prestigious journals such as New England Journal of Medicine, Proceedings of the National Academy of Sciences and Journal of Biological Chemistry.

In The Last Decade

Judith Falloon

91 papers receiving 6.5k citations

Hit Papers

HIV-1 and T cell dynamics... 1999 2026 2008 2017 1999 200 400 600
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. HIV-1 and T cell dynamics after interruption of highly active antiretroviral therapy (HAART) in patients with a history of sustained viral suppression
    1999 639 citations Richard T. Davey, Julia A. Metcalf et al. profile →

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author Last Decade Papers Cites
Judith Falloon 3.4k 3.3k 2.1k 1.8k 747 91 6.7k
Shinichi Oka 3.2k 0.9× 4.3k 1.3× 2.8k 1.3× 1.4k 0.8× 1.0k 1.4× 475 8.1k
Michael A. Polis 4.3k 1.3× 3.5k 1.1× 2.9k 1.4× 2.8k 1.5× 656 0.9× 143 8.6k
Richard T. Davey 6.3k 1.8× 6.2k 1.9× 3.2k 1.5× 3.5k 1.9× 1.2k 1.6× 170 11.8k
Michael H. Grieco 2.3k 0.7× 3.8k 1.1× 2.6k 1.2× 902 0.5× 589 0.8× 87 6.7k
Andrew D. Badley 2.7k 0.8× 2.7k 0.8× 1.8k 0.9× 2.0k 1.1× 1.4k 1.9× 195 6.6k
Julia A. Metcalf 5.9k 1.7× 4.0k 1.2× 1.9k 0.9× 4.4k 2.4× 1.4k 1.9× 103 9.9k
Hiroyuki Gatanaga 2.1k 0.6× 2.8k 0.8× 1.5k 0.7× 764 0.4× 623 0.8× 252 4.8k
Jacques Reynes 3.9k 1.1× 5.0k 1.5× 2.3k 1.1× 1.0k 0.6× 1.1k 1.5× 207 8.1k
Gerrit Jan Weverling 1.6k 0.5× 2.5k 0.8× 1.6k 0.7× 559 0.3× 640 0.9× 88 5.0k
Shyam Kottilil 1.8k 0.5× 1.9k 0.6× 3.8k 1.8× 2.6k 1.4× 680 0.9× 209 7.6k

Countries citing papers authored by Judith Falloon

Since Specialization
Citations

This map shows the geographic impact of Judith Falloon's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Judith Falloon with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Judith Falloon more than expected).

Fields of papers citing papers by Judith Falloon

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Judith Falloon. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Judith Falloon. The network helps show where Judith Falloon may publish in the future.

Co-authorship network of co-authors of Judith Falloon

This figure shows the co-authorship network connecting the top 25 collaborators of Judith Falloon. A scholar is included among the top collaborators of Judith Falloon based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Judith Falloon. Judith Falloon is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Weinberg, Adriana, Stacie Lambert, Jennifer Canniff, et al.. (2019). Antibody and B cell responses to an investigational adjuvanted RSV vaccine for older adults. Human Vaccines & Immunotherapeutics. 15(10). 2466–2474. 4 indexed citations
2.
Ruff, Christian T., Anton I. Rosenbaum, Sotirios K. Karathanasis, et al.. (2019). Abstract 12342: LEGACY: Phase 2a Trial to Evaluate the Safety, Pharmacokinetics and Pharmacodynamic Effects of the Anti-Endothelial Lipase Antibody MEDI5884 in Subjects With Stable CAD. Circulation. 1 indexed citations
3.
Ali, Omar, Xiang‐Qing Yu, Gabriel J. Robbie, et al.. (2018). Phase 1 study of MEDI3902, an investigational anti–Pseudomonas aeruginosa PcrV and Psl bispecific human monoclonal antibody, in healthy adults. Clinical Microbiology and Infection. 25(5). 629.e1–629.e6. 92 indexed citations
4.
Block, Stan L., Judith Falloon, Leonard R. Krilov, et al.. (2012). Immunogenicity and Safety of a Quadrivalent Live Attenuated Influenza Vaccine in Children. The Pediatric Infectious Disease Journal. 31(7). 745–751. 58 indexed citations
5.
Ambrose, Christopher S., Tingting Yi, & Judith Falloon. (2011). An integrated, multistudy analysis of the safety of Ann Arbor strain live attenuated influenza vaccine in children aged 2-17 years. Influenza and Other Respiratory Viruses. 5(6). 389–397. 29 indexed citations
6.
Ambrose, Christopher S., et al.. (2011). An Integrated, Multistudy Analysis of the Safety of Ann Arbor Strain Live Attenuated Influenza Vaccine in Children Aged 2-17 Years. Pediatric Research. 70. 479–479. 11 indexed citations
7.
Robertson, Sarah, Elizabeth Formentini, Raul M. Alfaro, et al.. (2006). Lack of sex‐related differences in saquinavir pharmacokinetics in an HIV‐seronegative cohort. British Journal of Clinical Pharmacology. 61(4). 379–388. 7 indexed citations
8.
Penzak, Scott, et al.. (2004). Ritonavir Decreases the Nonrenal Clearance of Digoxin in Healthy Volunteers with Known MDR1 Genotypes. Therapeutic Drug Monitoring. 26(3). 322–330. 54 indexed citations
9.
Piscitelli, Stephen C., Elizabeth Formentini, Aaron H. Burstein, et al.. (2002). Effect of Milk Thistle on the Pharmacokinetics of Indinavir in Healthy Volunteers. Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy. 22(5). 551–556. 93 indexed citations
10.
Kovacs, Joseph A., Richard A. Lempicki, Igor A. Sidorov, et al.. (2001). Identification of Dynamically Distinct Subpopulations of T Lymphocytes That Are Differentially Affected by HIV. The Journal of Experimental Medicine. 194(12). 1731–1741. 181 indexed citations
11.
Miller, Kirk D., Katherine Spooner, Betsey Herpin, et al.. (2001). Immunotherapy of HIV-Infected Patients with Intermittent Interleukin-2: Effects of Cycle Frequency and Cycle Duration on Degree of CD4+ T-Lymphocyte Expansion. Clinical Immunology. 99(1). 30–42. 16 indexed citations
12.
Kovacs, Joseph A., Hiromi Imamichi, Susan Vogel, et al.. (2000). Effects of Intermittent Interleukin‐2 Therapy on Plasma and Tissue Human Immunodeficiency Virus Levels and Quasi‐Species Expression. The Journal of Infectious Diseases. 182(4). 1063–1069. 25 indexed citations
13.
Falloon, Judith, Stephen C. Piscitelli, Brian M. Sadler, et al.. (2000). Combination Therapy with Amprenavir, Abacavir, and Efavirenz in Human Immunodeficiency Virus (HIV)-Infected Patients Failing a Protease-Inhibitor Regimen: Pharmacokinetic Drug Interactions and Antiviral Activity. Clinical Infectious Diseases. 30(2). 313–318. 65 indexed citations
14.
Yanovski, Jack A., Kirk D. Miller, Tomoshige Kino, et al.. (1999). Endocrine and Metabolic Evaluation of Human Immunodeficiency Virus-Infected Patients with Evidence of Protease Inhibitor-Associated Lipodystrophy. The Journal of Clinical Endocrinology & Metabolism. 84(6). 1925–1931. 122 indexed citations
15.
Davey, Richard T., Doreen Chaitt, Jeffrey M. Albert, et al.. (1999). A Randomized Trial of High‐ versus Low‐Dose Subcutaneous Interleukin‐2 Outpatient Therapy for Early Human Immunodeficiency Virus Type 1 Infection. The Journal of Infectious Diseases. 179(4). 849–858. 112 indexed citations
16.
Falloon, Judith, Stephen C. Piscitelli, Stephen W. LaFon, et al.. (1999). Atovaquone Suspension in HIV‐Infected Volunteers: Pharmacokinetics, Pharmacodynamics, and TMP‐SMX Interaction Study. Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy. 19(9). 1050–1056. 33 indexed citations
17.
Gea‐Banacloche, Juan, Claire W. Hallahan, Juan Carlos López Bernaldo de Quirós, et al.. (1998). Progression of Human Immunodeficiency Virus Disease Is Associated with Increasing Disruptions within the CD4+T Cell Receptor Repertoire. The Journal of Infectious Diseases. 177(3). 579–585. 29 indexed citations
18.
Avila, Nilo A., Andrew J. Dwyer, & Judith Falloon. (1997). Symptomatic appendiceal wall thickening in an HIV-infected patient caused by interleukin-2 therapy.. American Journal of Roentgenology. 169(2). 499–500. 1 indexed citations
19.
Davey, Richard T., Betsey Herpin, D. H. Batts, et al.. (1994). Use Of Recombinant Soluble Cd4 Pseudomonas Exotoxin, A Novel Immunotoxin, For Treatment Of Persons Infected With Human Immunodeficiency Virus. The Journal of Infectious Diseases. 170(5). 1180–1188. 37 indexed citations
20.
Kovacs, Joseph A., M. B. Vasudevachari, Richard T. Davey, et al.. (1993). Induction of humoral and cell-mediated anti-human immunodeficiency virus (HIV) responses in HIV sero-negative volunteers by immunization with recombinant gp160.. Journal of Clinical Investigation. 92(2). 919–928. 32 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Shinichi Oka Breakdown of academic impact, for papers by Michael A. Polis Breakdown of academic impact, for papers by Richard T. Davey Breakdown of academic impact, for papers by Michael H. Grieco Breakdown of academic impact, for papers by Andrew D. Badley Breakdown of academic impact, for papers by Julia A. Metcalf Breakdown of academic impact, for papers by Hiroyuki Gatanaga Breakdown of academic impact, for papers by Jacques Reynes Breakdown of academic impact, for papers by Gerrit Jan Weverling Breakdown of academic impact, for papers by Shyam Kottilil
Rankless by CCL
2026